MIRM
Mirum Pharmaceuticals, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 30 1:25-cv-01539 Mirum Pharmaceuticals, Inc. et al v. Zenara…
- Jun 2 Citigroup initiates
- Jun 17 ▼ 1 insider sell $264.5K at $101.95
- Jul 1 to Jul 6 ▼ 2 days of insider sells: $3.4M by 3 insiders, avg $122.04
- Aug 3 to Aug 18 ▼ 4 days of insider sells: $6.8M by 3 insiders, avg $99.82
- Sep 1 to Sep 2 ▼ 2 days of insider sells: $3.0M by 2 insiders, avg $98.71
- Sep 14 ▼ 1 insider sell $978.1K at $98.37
- Sep 30 ▲ 3 funds open new positions (13F)
- Nov 3 ▼ Earnings: MIRM Q3 2026 Earnings: EPS $-0.87 (-75.3% vs est)
- Nov 3 ▲ Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7M,…
- Nov 4 to Nov 11 ▼ 2 days of insider sells: $3.1M by 2 insiders, avg $91.75
- Nov 10 ▲ Mirum announced that its Phase 3 AZURE-4 study for brelovitug in chr…
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $17.6M.
- InstitutionsBULLISH
Q3 2026: 30 added (3 new), 16 trimmed or exited. Largest new: Jane Street Group $24.4M, Hrt Financial $14.9M.
- AnalystsBULLISH
20 of 21 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −2.1% to 6.52M shares. 11.8 days to cover, ≈10.0% of shares.
- TrendUPTREND
3% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | ADD | $61.7M |
| JANE STREET GROUP, LLC | NEW | $24.4M |
| Fisher Asset Management, LLC | DOUBLED | $16.8M |
| HRT FINANCIAL LP | NEW | $14.9M |
| FEDERATED HERMES, INC. | TRIM | $13.7M |
| JPMORGAN CHASE & CO | ADD | $12.1M |
| Nuveen, LLC | TRIM | $11.2M |
| BARCLAYS PLC | ADD | $8.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is below the lowest target. Median implies +69%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Citigroup MAINTAIN | Buy |
| Nov 5, 2026 | Leerink Partners MAINTAIN | Outperform |
| Nov 4, 2026 | RBC Capital REITERATE | Outperform |
| Nov 4, 2026 | Citizens MAINTAIN | Market Outperform |
| Nov 4, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Nov 4, 2026 | Cantor Fitzgerald MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Brege Laura Director Nov 11, 2026 | SELL | $1.0M |
Brege Laura Director Nov 11, 2026 | EXERCISE | $236.7K |
Brege Laura Director Nov 11, 2026 | SELL | $308.9K |
Peetz Christopher CHIEF EXECUTIVE OFFICER Nov 4, 2026 | EXERCISE | $58.7K |
Peetz Christopher CHIEF EXECUTIVE OFFICER Nov 4, 2026 | SELL | $1.8M |
Howe Jolanda SVP, GLOBAL CONTROLLER Oct 16, 2026 | EXERCISE | $310.0K |
Myers Robert Paul Chief Medical Officer Oct 9, 2026 | AWARD | 40,000 sh |
Myers Robert Paul Chief Medical Officer Oct 9, 2026 | AWARD | 25,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
27 filings · 9 bullish · 1 bearish · 3 mixed · 14 neutral- NEUTRAL SC 13G/ANov 16, 2026
Janus Henderson Group filed an amended Schedule 13G reporting a 8.5% passive stake in Mirum Pharmaceuticals as of September 30, 2026, representing 5,537,330 shares. This is an increase from the prior filing period, but as a passive institutional update it is routine and carries no directional…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL CLUSTERNov 13, 2026
Two Mirum insiders sold a combined $2.83M in open-market sales within a week of the company…
The CEO's sale was pre-planned under 10b5-1 and the director's sale followed option exercises, both small relative to market cap. No bearish signal from these trades; monitor next 8-K for any change…
- NEUTRAL 144Nov 12, 2026
Director Laura Brege filed a Form 144 to sell 14,167 shares of Mirum Pharmaceuticals, valued at…
The sale is small and routine for a director. No material impact expected. Monitor for any pattern of larger insider sales or changes in insider sentiment in future filings.
- BULLISH 8-KNov 10, 2026
Mirum announced that its Phase 3 AZURE-4 study for brelovitug in chronic hepatitis delta virus…
Monitor for BLA submission in H1 2027 and FDA acceptance/priority review. The AZURE-1 and AZURE-4 data package will be key for regulatory approval; any safety or efficacy concerns in the full…
All MIRM filing & press-release reports (27)
- SC 13G/A reportNov 16, 2026
- CLUSTER reportNov 13, 2026
- 144 reportNov 12, 2026
- 8-K reportNov 10, 2026
- 144 reportNov 4, 2026
- 144 reportNov 4, 2026
- 8-K reportNov 3, 2026
- INST-CLUSTER reportOct 27, 2026
- 8-K reportOct 26, 2026
- 8-K reportOct 13, 2026
- 8-K reportSep 28, 2026
- CLUSTER reportAug 19, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 11, 2026
- 144 reportAug 10, 2026
- 8-K reportAug 5, 2026
- CLUSTER reportJul 8, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 9, 2026
- CLUSTER reportJun 2, 2026
- 144 reportJun 1, 2026
- 144 reportJun 1, 2026
- 8-K reportMay 18, 2026
- 8-K reportMay 4, 2026
- 8-K reportApr 27, 2026
- 144 reportApr 15, 2026
- 8-K reportFeb 25, 2026